Literature DB >> 6126180

Ergonovine-induced constrictions of epicardial coronary arteries in conscious dogs: alpha-adrenoceptors are not involved.

J Holtz, W Held, O Sommer, G Kühne, E Bassenge.   

Abstract

The effect of i.v. ergonovine tartrate infusions (0.05-20 micrograms/kg/min, 12 minutes duration) on coronary arteries was studied in 14 conscious dogs instrumented to continuously measure vascular diameter by an ultrasonic dimension gauge using 10-MHz piezoelectric crystals. Ergonovine induced a biphasic coronary response: small, transient dilation during the first minutes of infusion, followed by slowly developing constriction reaching its maximum 5 to 15 minutes after the end of the infusion and persisting at this level for at least 10 minutes. The threshold dosage for significant constriction was 0.05 microgram/kg/min. A dosage of 5 micrograms/kg/min (cumulative 60 micrograms/kg, corresponding to 35 micrograms/kg ergonovine maleate) caused a decline in mean left circumflex artery diameter by 137 +/- 15 micrometers (= 4.6%) without significantly altering heart rate, plasma catecholamines or plasma renin activity. Coronary venous O2 saturation did not decline, indicating the absence of coronary resistance vessel constriction. The epicardial artery constriction was not attenuated by a vasopressin antagonist. Under adrenergic blockade (2 mg/kg phentolamine and 2 mg/kg nadolol) or under ganglionic blockade (5 mg/kg pentolinium tartrate), ergonovine (5 micrograms/kg /min) caused substantial elevation in mean arterial pressure, while the decline in coronary artery diameter was attenuated. When this increase in arterial pressure was prevented by appropriate bleeding, the ergonovine-induced coronary constriction was not diminished by adrenergic or ganglionic blockade. The serotonin antagonist methysergide (0.5 mg/kg) completely abolished the ergonovine-induced coronary artery vasomotion. It is concluded that ergonovine in dogs causes an epicardial coronary artery constriction comparable to the diffuse coronary artery narrowing in men not suffering from variant angina pectoris. These constrictions are not mediated by an adrenergic mechanism.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6126180     DOI: 10.1007/bf01908043

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  37 in total

1.  Measurement of multiple simultaneous small dimensions and study of arterial pressure-dimension relations in conscious animals.

Authors:  M Pagani; H Baig; A Sherman; W T Manders; P Quinn; T Patrick; D Franklin; S F Vatner
Journal:  Am J Physiol       Date:  1978-11

2.  Observations on the action of ergonovine on the coronary circulation and its use in the diagnosis of coronary artery insufficiency.

Authors:  I STEIN
Journal:  Am Heart J       Date:  1949-01       Impact factor: 4.749

3.  Segmental alpha-receptor-mediated vasoconstriction in the canine coronary circulation.

Authors:  K O Kelley; E O Feigl
Journal:  Circ Res       Date:  1978-12       Impact factor: 17.367

4.  Ergonovine maleate provocative test for coronary arterial spasm.

Authors:  F A Heupler; W L Proudfit; M Razavi; E K Shirey; R Greenstreet; W C Sheldon
Journal:  Am J Cardiol       Date:  1978-04       Impact factor: 2.778

5.  Evidence for 5-HT2 receptors mediating contraction in vascular smooth muscle.

Authors:  M L Cohen; R W Fuller; K S Wiley
Journal:  J Pharmacol Exp Ther       Date:  1981-08       Impact factor: 4.030

6.  Pathogenetic mechanisms underlying the clinical events associated with atherosclerotic heart disease.

Authors:  A Maseri; S Chierchia; A L'Abbate
Journal:  Circulation       Date:  1980-12       Impact factor: 29.690

7.  Altered adrenergic activity in coronary arterial spasm: insight into mechanism based on study of coronary hemodynamics and the electrocardiogram.

Authors:  D R Ricci; A E Orlick; P R Cipriano; D F Guthaner; D C Harrison
Journal:  Am J Cardiol       Date:  1979-06       Impact factor: 2.778

8.  Comparative effects of vasodilator drugs on large and small coronary resistance vessels in the dog.

Authors:  R Forman; E S Kirk
Journal:  Cardiovasc Res       Date:  1980-10       Impact factor: 10.787

9.  Effect of ergotamine and ergometrine on forearm venous compliance in man.

Authors:  O G Brooke; B F Robinson
Journal:  Br Med J       Date:  1970-01-17

10.  [1-beta-Mercapto-beta,beta-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine ]argine-vasopressin and [1-beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)]argine-vasopressine, two highly potent antagonists of the vasopressor response to arginine-vasopressin.

Authors:  M Kruszynski; B Lammek; M Manning; J Seto; J Haldar; W H Sawyer
Journal:  J Med Chem       Date:  1980-04       Impact factor: 7.446

View more
  12 in total

1.  Actions of non-peptide ergot alkaloids at 5-HT1-like and 5-HT2 receptors mediating vascular smooth muscle contraction.

Authors:  S J MacLennan; G R Martin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-08       Impact factor: 3.000

Review 2.  [Coronary spasm--a clinically relevant problem?].

Authors:  W Auch-Schwelk
Journal:  Herz       Date:  1998-03       Impact factor: 1.443

3.  Influence of the endothelium, nitric oxide and serotonergic receptors on coronary vasomotor responses evoked by ergonovine in conscious dogs.

Authors:  D Karila-Cohen; E Delpy; J L Dubois-Randé; L Puybasset; L Hittinger; J F Giudicelli; A Berdeaux
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

Review 4.  The role of serotonin in cardiovascular diseases and their treatment.

Authors:  P A van Zwieten; G J Blauw; P van Brummelen
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

5.  Mechanisms of ergonovine-induced hyperconstriction of coronary artery after x-ray irradiation in pigs.

Authors:  S Egashira; W Mitsuoka; H Tagawa; T Kuga; H Tomoike; M Nakamura; A Takeshita
Journal:  Basic Res Cardiol       Date:  1995 Mar-Apr       Impact factor: 17.165

6.  Comparison of contractile responses to 5-hydroxytryptamine and sumatriptan in human isolated coronary artery: synergy with the thromboxane A2-receptor agonist, U46619.

Authors:  T M Cocks; B K Kemp; D Pruneau; J A Angus
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

Review 7.  Endothelial vasomotor regulation in health and disease.

Authors:  N R Searle; P Sahab
Journal:  Can J Anaesth       Date:  1992-10       Impact factor: 5.063

Review 8.  Serotonin and the vascular system. Role in health and disease, and implications for therapy.

Authors:  D S Houston; P M Vanhoutte
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

9.  Effects of vasoactive stimuli on coronary vascular resistance in isolated perfused rabbit hearts: no vasospastic response to ergonovine with or without atherogenic diet.

Authors:  T von Arnim; F Crea; S Chierchia; G R Thompson; A Maseri
Journal:  Basic Res Cardiol       Date:  1983 Jul-Aug       Impact factor: 17.165

10.  Comparison of cardiac and hemodynamic effects of platelet-activating factor-acether and leukotriene D4 in anesthetized dogs.

Authors:  V B Fiedler; M Mardin; T S Abram
Journal:  Basic Res Cardiol       Date:  1987 Mar-Apr       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.